Severely obese preschoolers in a tertiary care obesity program: characteristics and management

Amy E Baughcum1, Kerri Gramling2, Ihuoma Eneli3

  • 1Center for Healthy Weight and Nutrition, Nationwide Children's Hospital, Columbus, OH, USA Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.

Clinical Pediatrics
|November 19, 2014
PubMed

Insights

Severely obese young children (2-5 years) referred to a specialized center often have high BMI z-scores and comorbidities. Multidisciplinary programs show promise for intervention, with improved retention potentially leading to better outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Public Health
  • Obesity Medicine

Background:

  • Severe obesity in early childhood (2-5 years) presents significant health challenges.
  • Tertiary care multidisciplinary centers are increasingly involved in managing pediatric obesity.

Purpose of the Study:

  • To characterize severely obese children aged 2-5 years referred to a specialized obesity center.
  • To describe their management and outcomes.

Main Methods:

  • Retrospective chart review of children aged 2-5 years with a body mass index (BMI) ≥95th percentile.
  • Data collected included demographics, BMI z-scores, family history, comorbidities, and follow-up outcomes.

Main Results:

  • 140 children (94% with BMI >99th percentile) were evaluated; 54% female, 48% Caucasian, mean age 4.6 years.
  • High mean BMI z-score (3.59) varied by age and gender; males and younger children had higher scores.
  • Prevalent comorbidities included dyslipidemia and eating behaviors; family history of obesity, type 2 diabetes, and hypertension was common.

Conclusions:

  • The study highlights the severity of obesity in young children referred to tertiary care.
  • Multidisciplinary programs show potential for intervention, emphasizing the need for improved patient retention for successful management.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
352
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
1.0K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
310
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
431
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.2K